CN105980370B - 稠合的杂环化合物 - Google Patents

稠合的杂环化合物 Download PDF

Info

Publication number: CN105980370B
Authority: CN; China
Prior art keywords: compound; examples; alkyl; group; acid
Prior art date: 2014-02-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

CN201580007800.9A

Other languages

English (en)

Chinese (zh)

Other versions

CN105980370A (zh

Inventor

佐佐木实

掛川佳子

菊地史朗

池田善

池田善一

西川洋

西川洋一

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sike Haiya Pharmaceutical Co ltd

Original Assignee

Takeda Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-02-13

Filing date

2015-02-12

Publication date

2018-03-02

2015-02-12 Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd

2016-09-28 Publication of CN105980370A publication Critical patent/CN105980370A/zh

2018-03-02 Application granted granted Critical

2018-03-02 Publication of CN105980370B publication Critical patent/CN105980370B/zh

Status Active legal-status Critical Current

2035-02-12 Anticipated expiration legal-status Critical

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Oncology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Immunology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Psychiatry (AREA)

CN201580007800.9A 2014-02-13 2015-02-12 稠合的杂环化合物 Active CN105980370B (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2014025832		2014-02-13
JP2014-025832		2014-02-13
PCT/JP2015/000639 WO2015122187A1 (en)	2014-02-13	2015-02-12	Fused heterocyclic compound

Publications (2)

Publication Number	Publication Date
CN105980370A CN105980370A (zh)	2016-09-28
CN105980370B true CN105980370B (zh)	2018-03-02

Family

ID=52589729

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN201580007800.9A Active CN105980370B (zh)	2014-02-13	2015-02-12	稠合的杂环化合物

Country Status (41)

Country	Link
US (2)	US9346776B2 (2)
EP (1)	EP3105213B1 (2)
JP (2)	JP6383427B2 (2)
KR (1)	KR102378454B1 (2)
CN (1)	CN105980370B (2)
AR (1)	AR099400A1 (2)
AU (1)	AU2015216438B2 (2)
BR (1)	BR112016018455B1 (2)
CA (1)	CA2938191C (2)
CL (1)	CL2016001911A1 (2)
CR (1)	CR20160367A (2)
CY (1)	CY1121534T1 (2)
DK (1)	DK3105213T3 (2)
DO (1)	DOP2016000206A (2)
EA (1)	EA032201B1 (2)
EC (1)	ECSP16067137A (2)
ES (1)	ES2717113T3 (2)
GE (1)	GEP20176808B (2)
HR (1)	HRP20190369T1 (2)
HU (1)	HUE042709T2 (2)
IL (1)	IL246838B (2)
JO (1)	JO3472B1 (2)
LT (1)	LT3105213T (2)
MA (1)	MA39246A1 (2)
ME (1)	ME03422B (2)
MX (1)	MX368392B (2)
MY (1)	MY173607A (2)
NZ (1)	NZ722035A (2)
PE (1)	PE20161243A1 (2)
PH (1)	PH12016501582B1 (2)
PL (1)	PL3105213T3 (2)
PT (1)	PT3105213T (2)
RS (1)	RS58498B1 (2)
SG (1)	SG11201605654QA (2)
SI (1)	SI3105213T1 (2)
SM (1)	SMT201900175T1 (2)
TR (1)	TR201903892T4 (2)
TW (1)	TWI669297B (2)
UA (1)	UA118280C2 (2)
UY (1)	UY35994A (2)
WO (1)	WO2015122187A1 (2)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG10201707504VA (en) *	2013-03-13	2017-10-30	Takeda Pharmaceuticals Co	Guanidinobenzoic acid ester compound
US9346776B2 (en)	2014-02-13	2016-05-24	Takeda Pharmaceutical Company Limited	Fused heterocyclic compound
US9428470B2 (en)	2014-02-13	2016-08-30	Takeda Pharmaceutical Company Limited	Heterocyclic compound
US9527835B2 (en)	2014-02-13	2016-12-27	Incyte Corporation	Cyclopropylamines as LSD1 inhibitors
EP3105218B1 (en)	2014-02-13	2019-09-25	Incyte Corporation	Cyclopropylamines as lsd1 inhibitors
JP6602779B2 (ja)	2014-02-13	2019-11-06	インサイト・コーポレイション	Ｌｓｄ１阻害剤としてのシクロプロピルアミン類
WO2016007731A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Imidazopyridines and imidazopyrazines as lsd1 inhibitors
US9695180B2 (en)	2014-07-10	2017-07-04	Incyte Corporation	Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9695167B2 (en)	2014-07-10	2017-07-04	Incyte Corporation	Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
JP2018080109A (ja) *	2015-03-16	2018-05-24	武田薬品工業株式会社	治療剤
JP6634070B2 (ja) *	2015-03-27	2020-01-22	武田薬品工業株式会社	縮合複素環化合物
EP3277689B1 (en)	2015-04-03	2019-09-04	Incyte Corporation	Heterocyclic compounds as lsd1 inhibitors
MY189367A (en)	2015-08-12	2022-02-08	Incyte Corp	Salts of an lsd1 inhibitor
BR112020008676A2 (pt)	2017-11-02	2020-10-27	Ube Industries, Ltd.	composto, e, composição farmacêutica.
UA126099C2 (uk)	2018-05-09	2022-08-10	ЕлДжи КЕМ, ЛТД.	Сполука, яка виявляє інгібувальну активність відносно ентеропептидази
TW202024028A (zh) *	2018-08-27	2020-07-01	日商思可海雅藥品股份有限公司	苯甲酸酯化合物
US10968200B2 (en)	2018-08-31	2021-04-06	Incyte Corporation	Salts of an LSD1 inhibitor and processes for preparing the same
WO2021013742A1 (en)	2019-07-19	2021-01-28	Janssen Pharmaceutica Nv	5,8-disubstituted-[1,2,4]triazolo[1,5-a]pyridinyl and 5,8-disubstituted-imidazo[1,2-a]pyridine derivatives useful as inhibitors of enteropeptidase
JP7327788B2 (ja) *	2019-08-06	2023-08-16	学校法人福岡大学	糖化産物生成抑制剤及び医薬組成物
WO2021166899A1 (ja) *	2020-02-17	2021-08-26	宇部興産株式会社	インクレチン様物質と組み合わせて使用するための消化管プロテアーゼ阻害剤を含む薬剤
CN111544599B (zh) *	2020-07-10	2020-12-01	有术肌肤管理(深圳)有限公司	一种用于治疗痤疮的化合物及其用于制备药物或化妆品的用途
CN111803652B (zh) *	2020-08-04	2021-09-14	南通康是美生物科技有限公司	治疗痤疮的化合物在制备治疗痤疮的药物组合物或化妆品组合物中的用途
US12029718B2 (en)	2021-11-09	2024-07-09	Cct Sciences, Llc	Process for production of essentially pure delta-9-tetrahydrocannabinol
TW202532060A (zh) *	2023-12-01	2025-08-16	日商Ｅａ製藥股份有限公司	醫藥組成物
WO2025115989A1 (ja) *	2023-12-01	2025-06-05	Ｅａファーマ株式会社	医薬組成物
WO2025211248A1 (ja) *	2024-04-04	2025-10-09	Ｅａファーマ株式会社	医薬組成物
WO2026063442A1 (ja) *	2024-09-18	2026-03-26	Ｅａファーマ株式会社	医薬組成物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH03200764A (ja) *	1989-12-28	1991-09-02	Snow Brand Milk Prod Co Ltd	新規グアニジノ安息香酸誘導体及びその酸付加塩
US5116985A (en) *	1989-12-28	1992-05-26	Snow Brand Milk Products Co., Ltd.	Isoquinoline derivatives and salts thereof
WO2007087130A2 (en) *	2006-01-12	2007-08-02	Merck & Co., Inc.	Hydroxyalkylarylamide derivatives
EP2511271A1 (en) *	2009-12-07	2012-10-17	Ajinomoto Co., Inc.	Heteroarylcarboxylic acid ester derivative
WO2013039187A1 (ja) *	2011-09-15	2013-03-21	アステラス製薬株式会社	グアニジノ安息香酸化合物
CN105051008A (zh) *	2013-03-13	2015-11-11	安斯泰来制药株式会社	胍基苯甲酸酯化合物

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5289640A (en)	1976-01-21	1977-07-27	Ono Pharmaceut Co Ltd	Guanidinobenzoic acid derivatives, and antiplasmin agents and remedies for pancreas diseases containing the said guanidinobensolc acid deriv atives
JPS5753454A (en)	1980-09-16	1982-03-30	Torii Yakuhin Kk	Guanidinobenzoate and anticomplementary agent
AU527371B2 (en)	1980-09-16	1983-03-03	Torii & Co., Ltd.	Amidine
JPH0446148A (ja)	1990-06-08	1992-02-17	Asahi Chem Ind Co Ltd	４―グアニジノ安息香酸フェニルエステル誘導体およびそれらを含有する蛋白分解酵素阻害剤
JPH06192085A (ja)	1992-08-31	1994-07-12	Yuji Inada	ダニアレルギー治療剤
EP0673924A4 (en)	1992-12-10	1996-04-24	Teikoku Chem Ind Co Ltd	PROPRIONIC ACID DERIVATIVE.
JPH0753500A (ja)	1993-08-16	1995-02-28	Sanwa Kagaku Kenkyusho Co Ltd	グアニジノ安息香酸誘導体及びこれらを有効成分とする蛋白分解酵素阻害剤
JPH0848664A (ja)	1994-08-05	1996-02-20	Hisamitsu Pharmaceut Co Inc	新規なグアニジノ安息香酸エステル誘導体
CN1072649C (zh)	1995-09-13	2001-10-10	武田药品工业株式会社	苯并氧杂吖庚因化合物,其生产方法和用途
JPH09124571A (ja)	1995-11-01	1997-05-13	Japan Tobacco Inc	アミド化合物及びその用途
US6388122B1 (en)	1996-04-10	2002-05-14	Ono Pharmaceutical Co., Ltd.	Tryptase inhibitor and novel guanidino derivatives
JPH10101556A (ja)	1996-09-27	1998-04-21	Ono Pharmaceut Co Ltd	ファクターｄ阻害剤
JPH10251239A (ja)	1997-03-14	1998-09-22	Mochida Pharmaceut Co Ltd	新規４ｈ−３，１−ベンゾオキサジン−４−オン誘導体
JPH10306025A (ja)	1997-05-07	1998-11-17	Touin Yokohama Univ	花粉プロテアーゼ阻害剤
AR035016A1 (es)	1999-08-25	2004-04-14	Takeda Chemical Industries Ltd	Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
CA2416384A1 (en)	2000-07-17	2003-01-16	Takeda Chemical Industries, Ltd.	Sulfone derivatives, their production and use
AU2003278600A1 (en)	2002-11-01	2004-05-25	Takeda Pharmaceutical Company Limited	Agent for preventing or treating neuropathy
CA2505322A1 (en)	2002-11-08	2004-05-21	Takeda Pharmaceutical Company Limited	Receptor function regulator
US20070004736A1 (en)	2002-11-22	2007-01-04	Keiji Kubo	Imidazole derivative, process for producing the same, and use
EP1630152A4 (en)	2003-05-30	2009-09-23	Takeda Pharmaceutical	CONDENSED CYCLIC COMPOUND
EP1669352A4 (en)	2003-09-30	2008-12-17	Takeda Pharmaceutical	THIAZOLINE DERIVATIVE AND ITS USE
EP1695961A4 (en)	2003-12-17	2007-10-24	Takeda Pharmaceutical	UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
AU2004309271A1 (en)	2003-12-25	2005-07-14	Takeda Pharmaceutical Company Limited	3-(4-benzyloxyphenyl)propanoic acid derivatives
WO2005063725A1 (ja)	2003-12-26	2005-07-14	Takeda Pharmaceutical Company Limited	フェニルプロパン酸誘導体
JP4875978B2 (ja)	2004-03-15	2012-02-15	武田薬品工業株式会社	アミノフェニルプロパン酸誘導体
US7517910B2 (en)	2004-03-30	2009-04-14	Takeda Pharmaceutical Company Limited	Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh)	2004-05-21	2013-05-21	Takeda Pharmaceutical	環狀醯胺衍生物、以及其製品和用法
JPWO2006057152A1 (ja)	2004-11-08	2008-06-05	小野薬品工業株式会社	タンパク質分解酵素阻害化合物からなる糖尿病治療剤
CA2588087A1 (en)	2004-11-15	2006-05-18	Obe Therapy Biotechnology S.A.S.	Methods of reducing body fat
WO2006057551A1 (en)	2004-11-26	2006-06-01	N.V. Nutricia	Infant nutrition with protease inhibitor
US8957070B2 (en)	2005-04-20	2015-02-17	Takeda Pharmaceutical Company Limited	Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
JP2006348023A (ja) *	2005-05-17	2006-12-28	Santen Pharmaceut Co Ltd	アミン誘導体を有効成分として含む血管新生阻害剤
EP1916234B1 (en)	2005-07-29	2014-11-12	Takeda Pharmaceutical Company Limited	Cyclopropanecarboxylic acid compound
US20090054435A1 (en)	2005-07-29	2009-02-26	Hiroshi Imoto	Phenoxyalkanoic Acid Compound
TW200740435A (en)	2005-08-10	2007-11-01	Takeda Pharmaceuticals Co	Therapeutic agent for diabetes
JP2007063225A (ja)	2005-09-01	2007-03-15	Takeda Chem Ind Ltd	イミダゾピリジン化合物
RS53230B (sr)	2006-06-27	2014-08-29	Takeda Pharmaceutical Company Limited	Kondenzovana ciklična jedinjenja kao modulatori gpr40 receptora
US8492405B2 (en)	2006-10-18	2013-07-23	Takeda Pharmaceutical Company Limited	Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
RU2454415C9 (ru)	2006-10-19	2013-02-27	Такеда Фармасьютикал Компани Лимитед	Производное индола
EP2128138A1 (en)	2007-01-29	2009-12-02	Takeda Pharmaceutical Company Limited	Pyrazole compound
JP2010517935A (ja)	2007-02-09	2010-05-27	武田薬品工業株式会社	Ｐｐａｒ−ガンマのパーシャルアゴニストとしての縮合環化合物
JPWO2008136428A1 (ja)	2007-04-27	2010-07-29	武田薬品工業株式会社	含窒素５員複素環化合物
WO2008156757A1 (en)	2007-06-19	2008-12-24	Takeda Pharmaceutical Company Limited	Indazole compounds for activating glucokinase
HRP20160569T1 (hr)	2007-12-03	2016-07-29	Obe Therapy Biotechnology	Boropeptidni inhibitori enteropeptidaze i njihove uporabe u liječenju pretilosti, pretjerane tjelesne težine i/ili bolesti povezane s abnormalnim metabolizmom masti
ES2618024T3 (es)	2011-06-07	2017-06-20	Ea Pharma Co., Ltd.	Derivado de éster de ácido carboxílico heterocíclico
EP3260131A1 (en)	2012-01-03	2017-12-27	Oramed Ltd.	Capsules containing oil-based liquid compositions of combined therapeutic agents for treating diabetes
US9024044B2 (en)	2012-06-14	2015-05-05	Ajinomoto Co., Inc.	Heteroarylcarboxylic acid ester derivative
WO2014106846A2 (en)	2013-01-03	2014-07-10	Oramed Ltd.	Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof
MX374512B (es)	2013-03-08	2025-03-06	Amgen Inc	Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso.
SMT202000071T1 (it)	2013-06-21	2020-03-13	Myokardia Inc	Composti di pirimidinadione contro le condizioni cardiache
JP6602779B2 (ja)	2014-02-13	2019-11-06	インサイト・コーポレイション	Ｌｓｄ１阻害剤としてのシクロプロピルアミン類
EP3105218B1 (en)	2014-02-13	2019-09-25	Incyte Corporation	Cyclopropylamines as lsd1 inhibitors
US9428470B2 (en)	2014-02-13	2016-08-30	Takeda Pharmaceutical Company Limited	Heterocyclic compound
US9346776B2 (en)	2014-02-13	2016-05-24	Takeda Pharmaceutical Company Limited	Fused heterocyclic compound

2015
- 2015-02-11 US US14/619,489 patent/US9346776B2/en active Active
- 2015-02-12 EA EA201691619A patent/EA032201B1/ru not_active IP Right Cessation
- 2015-02-12 AU AU2015216438A patent/AU2015216438B2/en active Active
- 2015-02-12 CA CA2938191A patent/CA2938191C/en active Active
- 2015-02-12 BR BR112016018455-6A patent/BR112016018455B1/pt active IP Right Grant
- 2015-02-12 MY MYPI2016702925A patent/MY173607A/en unknown
- 2015-02-12 HR HRP20190369TT patent/HRP20190369T1/hr unknown
- 2015-02-12 EP EP15706546.7A patent/EP3105213B1/en active Active
- 2015-02-12 ME MEP-2019-89A patent/ME03422B/me unknown
- 2015-02-12 KR KR1020167025277A patent/KR102378454B1/ko active Active
- 2015-02-12 US US15/117,538 patent/US9969705B2/en active Active
- 2015-02-12 CN CN201580007800.9A patent/CN105980370B/zh active Active
- 2015-02-12 LT LTEP15706546.7T patent/LT3105213T/lt unknown
- 2015-02-12 TW TW104104693A patent/TWI669297B/zh active
- 2015-02-12 RS RS20190324A patent/RS58498B1/sr unknown
- 2015-02-12 MA MA39246A patent/MA39246A1/fr unknown
- 2015-02-12 NZ NZ722035A patent/NZ722035A/en unknown
- 2015-02-12 ES ES15706546T patent/ES2717113T3/es active Active
- 2015-02-12 PT PT15706546T patent/PT3105213T/pt unknown
- 2015-02-12 CR CR20160367A patent/CR20160367A/es unknown
- 2015-02-12 SG SG11201605654QA patent/SG11201605654QA/en unknown
- 2015-02-12 PL PL15706546T patent/PL3105213T3/pl unknown
- 2015-02-12 GE GEAP201714261A patent/GEP20176808B/en unknown
- 2015-02-12 PE PE2016001239A patent/PE20161243A1/es unknown
- 2015-02-12 MX MX2016010559A patent/MX368392B/es active IP Right Grant
- 2015-02-12 JO JOP/2015/0028A patent/JO3472B1/ar active
- 2015-02-12 AR ARP150100411A patent/AR099400A1/es active IP Right Grant
- 2015-02-12 DK DK15706546.7T patent/DK3105213T3/en active
- 2015-02-12 JP JP2016550664A patent/JP6383427B2/ja active Active
- 2015-02-12 TR TR2019/03892T patent/TR201903892T4/tr unknown
- 2015-02-12 SM SM20190175T patent/SMT201900175T1/it unknown
- 2015-02-12 UY UY0001035994A patent/UY35994A/es not_active Application Discontinuation
- 2015-02-12 HU HUE15706546A patent/HUE042709T2/hu unknown
- 2015-02-12 SI SI201530626T patent/SI3105213T1/sl unknown
- 2015-02-12 WO PCT/JP2015/000639 patent/WO2015122187A1/en not_active Ceased
- 2015-12-02 UA UAA201609351A patent/UA118280C2/uk unknown
2016
- 2016-07-19 IL IL246838A patent/IL246838B/en active IP Right Grant
- 2016-07-28 CL CL2016001911A patent/CL2016001911A1/es unknown
- 2016-08-10 PH PH12016501582A patent/PH12016501582B1/en unknown
- 2016-08-11 EC ECIEPI201667137A patent/ECSP16067137A/es unknown
- 2016-08-11 DO DO2016000206A patent/DOP2016000206A/es unknown
2018
- 2018-08-03 JP JP2018146459A patent/JP6529649B2/ja active Active
2019
- 2019-03-27 CY CY20191100356T patent/CY1121534T1/el unknown

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH03200764A (ja) *	1989-12-28	1991-09-02	Snow Brand Milk Prod Co Ltd	新規グアニジノ安息香酸誘導体及びその酸付加塩
US5116985A (en) *	1989-12-28	1992-05-26	Snow Brand Milk Products Co., Ltd.	Isoquinoline derivatives and salts thereof
WO2007087130A2 (en) *	2006-01-12	2007-08-02	Merck & Co., Inc.	Hydroxyalkylarylamide derivatives
EP2511271A1 (en) *	2009-12-07	2012-10-17	Ajinomoto Co., Inc.	Heteroarylcarboxylic acid ester derivative
WO2013039187A1 (ja) *	2011-09-15	2013-03-21	アステラス製薬株式会社	グアニジノ安息香酸化合物
CN105051008A (zh) *	2013-03-13	2015-11-11	安斯泰来制药株式会社	胍基苯甲酸酯化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Synthesis and structure-activity relationship study of the new set of trypsin-like proteinase inhibitors;Pavol Zlatoidsky et al.;《Eur. J. Med. Chem.》;19991231;第34卷;第1023-1034页，尤其是Figure 1中的化合物2k *

Also Published As

Publication number	Publication date
JP6383427B2 (ja)	2018-08-29
UA118280C2 (uk)	2018-12-26
TWI669297B (zh)	2019-08-21
KR20160116002A (ko)	2016-10-06
MY173607A (en)	2020-02-10
IL246838B (en)	2020-01-30
LT3105213T (lt)	2019-03-12
US9346776B2 (en)	2016-05-24
RS58498B1 (sr)	2019-04-30
AR099400A1 (es)	2016-07-20
CA2938191A1 (en)	2015-08-20
MX368392B (es)	2019-10-01
PE20161243A1 (es)	2016-11-24
MX2016010559A (es)	2016-11-16
JP2017506627A (ja)	2017-03-09
TR201903892T4 (tr)	2019-04-22
JP6529649B2 (ja)	2019-06-12
TW201607936A (zh)	2016-03-01
US9969705B2 (en)	2018-05-15
DK3105213T3 (en)	2019-04-15
ES2717113T3 (es)	2019-06-19
IL246838A0 (en)	2016-08-31
NZ722035A (en)	2022-02-25
HRP20190369T1 (hr)	2019-05-03
EP3105213A1 (en)	2016-12-21
CN105980370A (zh)	2016-09-28
SG11201605654QA (en)	2016-08-30
PT3105213T (pt)	2019-04-16
US20150225361A1 (en)	2015-08-13
EP3105213B1 (en)	2019-01-09
EA032201B1 (ru)	2019-04-30
BR112016018455A2 (en)	2018-05-08
CY1121534T1 (el)	2020-05-29
ECSP16067137A (es)	2017-08-31
BR112016018455B1 (pt)	2022-09-06
UY35994A (es)	2015-08-31
AU2015216438B2 (en)	2018-12-06
US20160355494A1 (en)	2016-12-08
CA2938191C (en)	2021-08-31
SI3105213T1 (sl)	2019-05-31
WO2015122187A1 (en)	2015-08-20
CL2016001911A1 (es)	2017-02-10
KR102378454B1 (ko)	2022-03-23
JP2018197254A (ja)	2018-12-13
PH12016501582A1 (en)	2017-02-06
ME03422B (me)	2020-01-20
HUE042709T2 (hu)	2019-07-29
EA201691619A1 (ru)	2017-01-30
JO3472B1 (ar)	2020-07-05
DOP2016000206A (es)	2018-01-31
AU2015216438A1 (en)	2016-07-21
PL3105213T3 (pl)	2019-06-28
SMT201900175T1 (it)	2019-05-10
MA39246A1 (fr)	2018-05-31
PH12016501582B1 (en)	2019-03-13
GEP20176808B (en)	2018-01-10
CR20160367A (es)	2016-12-01

Legal Events

Date	Code	Title	Description
2016-09-28	C06	Publication
2016-09-28	PB01	Publication
2016-10-26	C10	Entry into substantive examination
2016-10-26	SE01	Entry into force of request for substantive examination
2018-03-02	GR01	Patent grant
2018-03-02	GR01	Patent grant
2021-01-29	TR01	Transfer of patent right
2021-01-29	TR01	Transfer of patent right	Effective date of registration: 20210119 Address after: Kanagawa, Japan Patentee after: Sike Haiya Pharmaceutical Co.,Ltd. Address before: Osaka Japan Patentee before: TAKEDA PHARMACEUTICAL Co.,Ltd.

Publication	Publication Date	Title
CN105980370B (zh)	2018-03-02	稠合的杂环化合物
JP6458054B2 (ja)	2019-01-23	複素環化合物
CN110719903A (zh)	2020-01-21	芳族环化合物
JP2020512387A (ja)	2020-04-23	代謝性障害の治療の為の置換シクリル酢酸誘導体
US9975903B2 (en)	2018-05-22	Condensed heterocyclic compound
US10017487B2 (en)	2018-07-10	Fused heterocyclic compound